CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

601

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Cervix Cancer
Interventions
RADIATION

Radiotherapy

"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"

RADIATION

Radiotherapy

"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"

RADIATION

Radiotherapy/Cisplatin

"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"

RADIATION

Radiotherapy/Cisplatin

"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"

Trial Locations (11)

Unknown

University of Vienna; Department of Radiotherapy and Radiobiology, Vienna

rmandade de Santa Casa de Misericordia de Porto Alegre; Hospital Santa Rita, Porto Alegre

Peel Regional Cancer Centre, Mississauga

Department of Atomic Energy (DAE); Tata Memorial Centre (TMC); Tata, Mumbai

Institut National d'Oncologie, Rabat

Radiotherapy and Oncology University Clinic, Skopje

Bahawalpur Institute of Nuclear Medicine and Oncology (BINO), Bahawalpur

Instituto Nacional de Enfermedades Neoplásicas, Lima

Department of Radiation Oncology, Groote Schuur Hospital, Cape Town

National Cancer Center, Seoul

Christie Hospital; NHS Trust, Manchester

All Listed Sponsors
lead

International Atomic Energy Agency

OTHER_GOV

NCT00122772 - CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy | Biotech Hunter | Biotech Hunter